Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: VolitionRx Limited

Market Cap 10.08M 8.85M 8.16M 7.64M 14.31M 955M 14.55M 97.97M 37.92M 468M 37.84M 37.02M 1.63B P/E 2026 *
-0.54x
P/E 2027 * -0.87x
Enterprise Value 10.08M 8.85M 8.16M 7.64M 14.31M 955M 14.55M 97.97M 37.92M 468M 37.84M 37.02M 1.63B EV / Sales 2026 *
4.07x
EV / Sales 2027 * 1.76x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-9.70%
1 week-13.57%
Current month-54.68%
1 month-61.34%
3 months-70.55%
6 months-76.25%
Current year-76.33%
1 week 1.2
Extreme 1.205
1.48
1 month 1.2
Extreme 1.205
3.2
Current year 1.2
Extreme 1.205
7.73
1 year 1.2
Extreme 1.205
18.4
3 years 1.2
Extreme 1.205
31
5 years 1.2
Extreme 1.205
82.8
10 years 1.2
Extreme 1.205
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-17Tax

Chief Technology Officer

5,310 0.0039%
03-17
Concord International, Inc.
OtherCompany 0 0%
03-17Tax

Company Secretary

3,948 0.0029%
Change 5-day change 1-year change 3-year change Capi.($)
-9.70%-13.57%-92.97%-95.97% 10.08M
+1.13%+5.64%+101.39%+110.69% 4.29B
-0.81%+0.06%+63.16%+148.27% 2.76B
-1.59%+5.91%-24.65%-39.73% 2.04B
+9.36%+16.23%+140.00%-44.98% 1.98B
+0.28%+8.04%+32.56%+218.78% 1.3B
-0.18%-5.09%-18.52%+27.00% 814M
+2.29%+7.19%+154.50%-58.91% 792M
+0.25%-5.33%-31.46%-16.73% 500M
-14.23%-31.94%+23.75% - 474M
Average -1.32%-1.99%+34.78%+27.60% 1.5B
Weighted average by Cap. +0.89%+3.89%+65.59%+66.55%

Financials

2026 *2027 *
Net sales 2.48M 2.18M 2.01M 1.88M 3.52M 235M 3.58M 24.08M 9.32M 115M 9.3M 9.1M 400M 5.73M 5.04M 4.64M 4.34M 8.14M 543M 8.28M 55.73M 21.57M 266M 21.52M 21.06M 926M
Net income -22.2M -19.51M -17.97M -16.83M -31.52M -2.1B -32.05M -216M -83.54M -1.03B -83.35M -81.56M -3.59B -19.62M -17.24M -15.88M -14.87M -27.85M -1.86B -28.32M -191M -73.82M -912M -73.65M -72.06M -3.17B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
23/06/26 $1.210 -9.70% 477,490
22/06/26 $1.340 -6.29% 294,397
18/06/26 $1.430 +4.38% 296,387
17/06/26 $1.370 -2.14% 402,571
16/06/26 $1.400 -2.78% 550,310
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.210USD
Average target price
16.97USD
Spread / Average Target
+1,302.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!